Filing Flows › Industrials › Quanterix (QTRX)
Quanterix (QTRX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 10, 2026 · Quanterix (QTRX) Q2 2026 earnings results →
Q2 2026 Revenue up 34% year over year to $32.9M · 149¢ of every $1 of revenue lost · operating margin -150.2%
Quanterix made $32.9M in Q2 2026 (+34% Y/Y): Product revenue $23.4M, Spatial biology $9.3M. Operating margin -150.2%, net loss $48.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 10, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $32.9M in Q2 2026, up 34% year over year and down 10% from the previous quarter. Spatial biology was the largest line at 28% of revenue. Service and other revenue added $1.9M year over year (up 27%), 23% of the total change. Research services declined 26%.
Gross margin was 38.5%, down 2.3 points from Q2 2025. Operating costs exceeded revenue by $49.4M, an operating margin of -150.2%. Operating expenses grew 32% against revenue growth of 34%. The fastest-growing cost line was Other operating costs (+251%). The quarter ended with a net loss of $48.9M, wider than the previous quarter's $17.5M loss.
Operating cash flow was −$5.1M. Non-cash charges added back $6.1M of depreciation and amortization and $4.2M of share-based compensation. Working capital and other items added $33.5M. Capital expenditures of $96K exceeded it, leaving free cash flow of −$5.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 10, 2026 | $32.9M | +34% | -150.2% | −$48.9M | −$5.1M |
| Q1 2026 | 10-Q | May 6, 2026 | $36.4M | +20% | -113.6% | −$17.5M | −$18.1M |
| Q4 2025 | 10-K | Mar 2, 2026 | $43.9M | +25% | -56.4% | −$23.1M | −$16.4M |
| Q3 2025 | 10-Q | Nov 10, 2025 | $40.2M | +12% | -92.8% | −$33.5M | −$41.2M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $24.5M | -29% | -151.6% | −$30.0M | −$5.7M |
| Q1 2025 | 10-Q | May 12, 2025 | $30.3M | -5% | -86.9% | −$20.5M | −$13.9M |
| Q4 2024 | 10-K | Mar 17, 2025 | $35.2M | +11% | -42.0% | −$11.6M | −$4.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Quanterix
We are a life sciences company transforming healthcare innovation by accelerating biomarker breakthroughs from discovery to diagnostics using our ultra-sensitive translational research and spatial biology instruments, consumables, and services. We continue to invest in pushing a paradigm shift in healthcare from an emphasis on later-stage treatment to a focus on earlier detection, monitoring, prognosis, and, ultimately, prevention. Our combined platforms have achieved significant commercial adoption with an installed base of over 2,500 instruments and scientific validation with citations in more than 6,200 scientific publications in areas of high unmet medical need and research interest such as neurology, oncology, immunology, and inflammation.
In its own words, from its 10-K, filed Mar 2, 2026.
Quanterix against its Laboratory Analytical Instruments peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +34% against the peers' median +5%. Operating margin: -150.2% against the peers' median 8.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| QTRX Quanterix | Q2 2026 | $32.9M | +34% | -150.2% |
| A Agilent Technologies | Q3 FY26 | $1.9B | +8% | 23.6% |
| WAT Waters | Q3 2026 | $1.8B | +121% | 7.2% |
| AVTR Avantor | Q3 2026 | $1.7B | +5% | 8.2% |
| ILMN Illumina | Q3 2026 | $1.1B | +4% | 27.0% |
| MTD Mettler Toledo International | Q3 2026 | $1.1B | +6% | 27.4% |
| BRKR Bruker | Q3 2026 | $874M | +2% | -10.4% |
| RVTY Revvity | Q3 2026 | $729M | +4% | 10.6% |
| BIO Bio-Rad Laboratories | Q3 2026 | $656M | +0.5% | -7.6% |
Source: Quanterix 10-Q on SEC EDGAR · CIK 1503274 · Laboratory Analytical Instruments
13F: who owns QTRX and who is buying
More on QTRX
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results